Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AML

Stefan Faderl, MD
Published: Friday, Apr 11, 2014

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).

As with all agents being explored in AML, there is interest in using FLT3 inhibitors in combination with chemotherapy, though discussion remains regarding sequencing. Faderl says he believes there is interest in both moving away from intensive chemotherapy for the treatment of AML and combining FLT3 inhibitors with lower-intensity therapies.

Stefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).

As with all agents being explored in AML, there is interest in using FLT3 inhibitors in combination with chemotherapy, though discussion remains regarding sequencing. Faderl says he believes there is interest in both moving away from intensive chemotherapy for the treatment of AML and combining FLT3 inhibitors with lower-intensity therapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x